| 货号 | 13325-5mg |
| 描述 | Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression whose function/dysfunction has been implicated in cancer, a subset of human neurodegenerative diseases, and the reward response of addictive drugs via alteration of postsynaptic dopamine receptor signaling. Iso-olomoucine is an inactive stereoisomer of the Cdk5 inhibitor olomoucine. Because iso-olomoucine lacks activity at Cdk5 (IC50 ≥ 1 mM)1, it may have utility as a control compound for determining Cdk5 specificity.2,3,4 In a Cdk5-independent manner, iso-olomoucine has been shown to rapidly inhibit dopamine transporter activity in rat dorsal striatal synaptosomes with a potency similar to that of olomoucine (IC50 ~37 μM).2 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Vesely, J.,Havlicek, J.,Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994). 2.Price, D.A.,Sorkin, A. and Zahniser, N.R. Cyclin-dependent kinase 5 inhibitors: Inhibition of dopamine transporter activity. Molecular Pharmacology 76(4), 812-823 (2009). 3.Taylor, J.R.,Lynch, W.J.,Sanchez, H., et al. Inhibition of Cdk5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaine. Proceedings of the National Academy of Sciences of the United States of America 104(10), 4147-4152 (2007). 4.Fletcher, A.I.,Shuang, R.,Giocannucci, D.R., et al. Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18*. The Journal of Biological Chemisty 274(7), 4027-4035 (1999). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 298.3 |
| 分子式 | C15H18N6O |
| CAS号 | 101622-50-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |